# Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

> **NCT07681076** · PHASE4 · RECRUITING · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 225 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** KarXT
- **DRUG:** Trimethobenzamide
- **DRUG:** Ondansetron
- **DRUG:** Meclizine

## Key facts

- **NCT ID:** NCT07681076
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-03
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681076, "Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*